Abstract
Objectives
Participants and Methods
Results
Conclusion
Abbreviations and Acronyms:
Δ (difference between baseline and follow-up), BMI (body mass index), CK (creatine kinase), LDL-C (low-density lipoprotein cholesterol), MET-h/d (metabolic equivalents-hours per day), VO2max (maximum oxygen consumption)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsReferences
- Statin-associated myopathy.JAMA. 2003; 289: 1681-1690
- Muscle- and skeletal-related side-effects of statins: tip of the iceberg [published online September 17, 2014]?.Eur J Prev Cardiol. 2014;
- The effects of statin medications on aerobic exercise capacity and training adaptations.Sports Med. 2014; 44: 1519-1530
- Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins.Toxicol Appl Pharmacol. 2012; 259: 263-268
- Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.Clin Pharmacol Ther. 2007; 81: 650-653
- Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy.J Neurol Sci. 2013; 325: 142-147
- Statins and physical activity in older men: the osteoporotic fractures in men study.JAMA Intern Med. 2014; 174: 1263-1270
- A systematic review of statin-induced muscle problems in clinical trials.Am Heart J. 2014; 168: 6-15
- Risks associated with statin therapy: a systematic overview of randomized clinical trials.Circulation. 2006; 114: 2788-2797
- Changes in muscle strength in patients with statin myalgia.Am J Cardiol. 2014; 114: 1215-1216
- The effect of statins on skeletal muscle function.Circulation. 2013; 127: 96-103
- Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.Atherosclerosis. 2013; 230: 121-124
- Vigorous exercise, fitness and incident hypertension, high cholesterol, and diabetes.Med Sci Sports Exerc. 2008; 40: 998-1006
- Walking versus running for hypertension, cholesterol, and diabetes mellitus risk reduction.Arterioscler Thromb Vasc Biol. 2013; 33: 1085-1091
- Incident hypercholesterolemia in relation to changes in vigorous physical activity.Med Sci Sports Exerc. 2009; 41: 74-80
- Vigorous exercise and diabetic, hypertensive, and hypercholesterolemia medication use.Med Sci Sports Exerc. 2007; 39: 1933-1941
- Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners: the National Runners' Health Study.Arch Intern Med. 1997; 157: 191-198
- Non-exchangeability of running vs. other exercise in their association with adiposity, and its implications for public health recommendations.PLoS One. 2012; 7: e36360
- Advantage of distance- versus time-based estimates of walking in predicting adiposity.Med Sci Sports Exerc. 2012; 44: 1728-1737
- An experimental study of physical fitness of Air Force personnel.U S Armed Forces Med J. 1959; 10: 875-888
- Limitations of marathon running in the rehabilitation of coronary patients: anatomic and physiologic determinants.Ann N Y Acad Sci. 1977; 301: 484-494
- A means of assessing maximal oxygen intake: correlation between field and treadmill testing.JAMA. 1968; 203: 201-204
- Statin use and self-reported swimming performance in US masters swimmers.J Sports Sci. 2015; 33: 1-7
- High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.Age (Dordr). 2008; 30: 283-291
- Statins and activity, proceed with caution.JAMA Intern Med. 2014; 174: 1270-1272
- 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014; 63: 2960-2984
- Lipoprotein subfractions of runners and sedentary men.Metabolism. 1986; 35: 45-52
- Simvastatin impairs exercise training adaptations.J Am Coll Cardiol. 2013; 62: 709-714
- Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.J Appl Physiol (1985). 2012; 113: 479-486
- Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress.J Appl Physiol. 2011; 111: 1477-1483
- Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.Metabolism. 2009; 58: 1030-1038
- Statin therapy does not attenuate exercise training response in cardiac rehabilitation.J Am Coll Cardiol. 2014; 63: 2050-2051
- Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.Fundam Clin Pharmacol. 2005; 19: 117-125
- High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.Clin Pharmacol Ther. 2005; 78: 60-68
- Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study.Cardiovasc Drugs Ther. 2005; 19: 403-414
- Mitochondria of trained skeletal muscle are protected from deleterious effects of statins.Muscle Nerve. 2012; 46: 367-373
- Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.Toxicol Appl Pharmacol. 2004; 194: 10-23
- Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.Toxicol Pathol. 2005; 33: 246-257
- Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise.Muscle Nerve. 2011; 44: 882-889
- Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice.Pharmacol Rep. 2012; 64: 1326-1336
- Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.Br J Clin Pharmacol. 2004; 57: 525-528
- Evidence-based nutrition: the impact of information and selection bias on the interpretation of individual studies.South Afr J Clin Nutr. 2003; 16: 78-87
- Memory and mismemory for health events.in: Tanur J.M. Questions About Questions: Inquiries Into the Cognitive Bases of Surveys. Russell Sage Foundation, New York, NY1991: 102-137
Article Info
Footnotes
For editorial comment, see page 1314
Potential Competing Interests: Dr Thompson has received research support from Genomas, Sanolfi, Regeneron, Esperion, Amarin, and Pfizer; has served as a consultant for Amgen, Regeneron, Merck, and Sanolfi; has received speaker honoraria from Merck and AstraZeneca; owns stock in Abbvie, Abbott Labs, General Electric, Johnson & Johnson, and JA Willey; and has provided expert legal testimony on exercise-related cardiac events and statin myopathy.